Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine
Peter J. Goadsby(King's College London), Charly Gaul(Cardiovascular Center Frankfurt), Bernice Kuca(Eli Lilly (United States)), Ellen B. Dennehy(Purdue University West Lafayette), Michael Case(Eli Lilly (United States)), Sheena K. Aurora(Impel Neuropharma (United States)), Linda Wietecha(Eli Lilly (United States))
Cited by 275
Related Papers
The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation
|Psychological Medicine|2004|989
Effectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression
|New England Journal of Medicine|2007|925
CGRP and the Trigeminal System in Migraine
|Headache The Journal of Head and Face Pain|2019|483
Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults
|Cephalalgia|2018|382
Trial of Solanezumab in Preclinical Alzheimer’s Disease
|New England Journal of Medicine|2023|382